Epidemiology of IGF-1 and cancer

Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics

Volumn , Issue , 2012, Pages 1-24

  Nimptsch, Katharina ^a   Giovannucci, Edward ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905196516     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0598-6_1     Document Type: Chapter

References (108)

1. Albanes, D., S. J. Weinstein, et al. (2009). "Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer." J Natl Cancer Inst 101(18):1272-9.
2. Allen, N. E., T. J. Key, et al. (2007). "Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition." Cancer Epidemiol. Biomarkers Prev 16(6):1121-1127.
3. Allen, N. E., A. W. Roddam, et al. (2005). "A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk." Br J Cancer 92(7):1283-7.
4. Baglietto, L., D. R. English, et al. (2007). "Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer." Cancer Epidemiol Biomarkers Prev 16(4):763-8.
5. Baxter, R. C. (2001). "Signalling pathways involved in antiproliferative effects of IGFBP-3: a review." Mol Pathol 54(3):145-8.
6. Becker, S. and R. Kaaks (2009). "Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk?" Recent Results Cancer Res 181: 135-57.
7. Bohlke, K., D. W. Cramer, et al. (1998). "Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast." Epidemiology 9(5):570-3.
8. Brabant, G. and H. Wallaschofski (2007). "Normal levels of serum IGF-I: determinants and validity of current reference ranges." Pituitary 10(2):129-33.
9. Bruning, P. F., J. Van Doorn, et al. (1995). "Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer." Int J Cancer 62(3):266-70.
10. Brunner, J. E., C. C. Johnson, et al. (1990). "Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer." Clin Endocrinol (Oxf) 32(1):65-71.
11. Cats, A., R. P. Dullaart, et al. (1996). "Increased epithelial cell proliferation in the colon of patients with acromegaly." Cancer Res 56(3):523-6.
12. Chan, J. M., M. J. Stampfer, et al. (1998). "Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study." Science 279(5350):563-6.
13. Chan, J. M., M. J. Stampfer, et al. (2002). "Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer." J Natl Cancer Inst 94(14):1099-106.
14. Chen, C., S. K. Lewis, et al. (2005). "Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin." Cancer 103(1):76-84.
15. Cohen, P., D. M. Peehl, et al. (1993). "Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients." J Clin Endocrinol Metab 76(4):1031-5.
16. Colao, A., R. Pivonello, et al. (2007). "The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients." J Clin Endocrinol Metab 92(10):3854-60.
17. Dupont, J. and D. Le Roith (2001). "Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects." Mol Pathol 54(3):149-54.
18. Eliassen, A. H., S. S. Tworoger, et al. (2007). "Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women." Cancer Epidemiol Biomarkers Prev 16(1):161-4.
19. Engeland, A., S. Tretli, et al. (2005). "Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women." Cancer Causes Control 16(8):987-96.
20. Finne, P., A. Auvinen, et al. (2000). "Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen." J Clin Endocrinol Metab 85(8):2744-7.
21. Fletcher O., L. Gibson, et al. (2005). "Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review." Cancer Epidemiol Biomarkers Prev 14(1):2-19.
22. Foltyn, W., B. Kos-Kudla, et al. (2008). "Is there any relation between hyperinsulinemia, insulin resistance and colorectal lesions in patients with acromegaly?" Neuro Endocrinol Lett 29(1):107-12.
23. Furstenberger, G. and H. J. Senn (2002). "Insulin-like growth factors and cancer." Lancet Oncol 3(5):298-302.
24. Giovannucci, E. (2001). "Insulin, insulin-like growth factors and colon cancer: a review of the evidence." J Nutr 131(11 Suppl): 3109S-20S.
25. Giovannucci, E., Y. Liu, et al. (2007). "Risk factors for prostate cancer incidence and progression in the health professionals follow-up study." Int J Cancer.
26. Giovannucci, E., M. Pollak, et al. (2003). "Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men." Cancer Epidemiol Biomarkers Prev 12(2):84-9.
27. Giovannucci, E., M. N. Pollak, et al. (2000). "A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women." Cancer Epidemiol Biomarkers Prev 9(4):345-9.
28. Giovannucci, E., E. B. Rimm, et al. (2004). "Height, predictors of C-peptide and cancer risk in men." Int J Epidemiol 33(1):217-25.
29. Glass, A. R., J. W. Kikendall, et al. (1994). "Serum concentrations of insulin-like growth factor 1 in colonic neoplasia." Acta Oncol 33(1):70-1.
30. Gronbaek, H., A. Flyvbjerg, et al. (2004). "Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women." Cancer Epidemiol Biomarkers Prev 13(11 Pt 1): 1759-64.
31. Gunter, M. J., D. R. Hoover, et al. (2008). "Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women." Cancer Res 68(1):329-37.
32. Gunter, M. J., D. R. Hoover, et al. (2009). "Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women." J Natl Cancer Inst 101(1):48-60.
33. Hankinson, S. E., W. C. Willett, et al. (1998). "Circulating concentrations of insulin-like growth factor-I and risk of breast cancer." Lancet 351(9113):1393-6.
34. Harman, S. M., E. J. Metter, et al. (2000). "Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer." J Clin Endocrinol Metab 85(11):4258-65.
35. Harrela, M., H. Koistinen, et al. (1996). "Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3." J Clin Invest 98(11):2612-5.
36. Holmes, M. D., M. N. Pollak, et al. (2002). "Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations." Cancer Epidemiol Biomarkers Prev 11(9):852-61.
37. Hsing, A. W., Y. T. Gao, et al. (2003). "Insulin resistance and prostate cancer risk." J Natl Cancer Inst 95(1):67-71.
38. Hsing, A. W., L. C. Sakoda, et al. (2007). "Obesity, metabolic syndrome, and prostate cancer." Am J Clin Nutr 86(3): s843-57.
39. IARC (2008). World Cancer Report 2008. Lyon, World Health Organization, International Agency for Research on Cancer.
40. Jenkins, P. J. (2004). "Acromegaly and cancer." Horm Res 62 Suppl 1: 108-15.
41. Jenkins, P. J., P. D. Fairclough, et al. (1997). "Acromegaly, colonic polyps and carcinoma." Clin Endocrinol (Oxf) 47(1):17-22.
42. Jenkins, P. J., V. Frajese, et al. (2000). "Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly." J Clin Endocrinol Metab 85(9):3218-21.
43. Johansson, M., J. D. McKay, et al. (2009). "Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival." Prostate 69(12):1281-91.
44. Juul, A., P. Bang, et al. (1994). "Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index." J Clin Endocrinol Metab 78(3):744-52.
45. Kaaks, R. (2004). "Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence." Novartis Found Symp 262: 247-60; discussion 260-68.
46. Kaaks, R. and A. Lukanova (2001). "Energy balance and cancer: the role of insulin and insulin-like growth factor-I." Proc Nutr Soc 60(1):91-106.
47. Kaaks, R., E. Lundin, et al. (2002). "Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden." Cancer Causes Control 13(4):307-16.
48. Kaaks, R., P. Toniolo, et al. (2000). "Serum C-peptide, insulin-like growth factor (IGF)-I, IGF- binding proteins, and colorectal cancer risk in women." J Natl Cancer Inst 92(19):1592-600.
49. Kanety, H., Y. Madjar, et al. (1993). "Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen." J Clin Endocrinol Metab 77(1):229-33.
50. Keinan-Boker, L., H. B. Bueno De Mesquita, et al. (2003). "Circulating levels of insulin-like growth factor I, its binding proteins -1, -2, -3, C-peptide and risk of postmenopausal breast cancer." Int J Cancer 106(1):90-5.
51. Key, T. J., P. N. Appleby, et al. (2010) "Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies." Lancet Oncol 11(6):530-42.
52. Krajcik, R. A., N. D. Borofsky, et al. (2002). "Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer." Cancer Epidemiol Biomarkers Prev 11(12):1566-73.
53. Lacey, J. V., Jr., A. W. Hsing, et al. (2001). "Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study." Cancer Epidemiol Biomarkers Prev 10(10):1101-2.
54. Larsson, S. C., N. Orsini, et al. (2005). "Diabetes mellitus and risk of colorectal cancer: a metaanalysis." J Natl Cancer Inst 97(22):1679-87.
55. Ma, J., E. Giovannucci, et al. (2004). "A prospective study of plasma C-peptide and colorectal cancer risk in men." J Natl Cancer Inst 96(7):546-53.
56. Ma, J., H. Li, et al. (2008). "Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis." Lancet Oncol 9(11):1039-47.
57. Ma, J., M. N. Pollak, et al. (1999). "Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3." J Natl Cancer Inst 91(7):620-5.
58. Manousos, O., J. Souglakos, et al. (1999). "IGF-I and IGF-II in relation to colorectal cancer." Int J Cancer 83(1):15-7.
59. Mantzoros, C. S., A. Tzonou, et al. (1997). "Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia." Br J Cancer 76(9):1115-8.
60. Max, J. B., P. J. Limburg, et al. (2008). "IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: no association with incident colorectal cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study." Cancer Epidemiol Biomarkers Prev 17(7):1832-4.
61. McMenamin, M. E., P. Soung, et al. (1999). "Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage." Cancer Res 59(17):4291-6.
62. Meyer, F., P. Galan, et al. (2005). "A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial." Cancer Epidemiol Biomarkers Prev 14(9):2269-72.
63. Monti, S., L. Proietti-Pannunzi, et al. (2007). "The IGF axis in prostate cancer." Curr Pharm Des 13(7):719-27.
64. Morris, J. K., L. M. George, et al. (2006). "Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies." Br J Cancer 95(1):112-7.
65. Muti, P., T. Quattrin, et al. (2002). "Fasting glucose is a risk factor for breast cancer: a prospective study." Cancer Epidemiol Biomarkers Prev 11(11):1361-8.
66. Nimptsch, K., E. A. Platz, et al. (2010). "Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004." Int J Cancer.
67. Nomura, A. M., G. N. Stemmermann, et al. (2003). "Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men." Am J Epidemiol 158(5):424-31.
68. Otani, T., M. Iwasaki, et al. (2005). "Body mass index, body height, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan public health center-based prospective study." Cancer Causes Control 16(7):839-50.
69. Otani, T., M. Iwasaki, et al. (2007). "Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study." Int J Cancer 120(9):2007-12.
70. Palmqvist, R., G. Hallmans, et al. (2002). "Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden." Gut 50(5):642-6.
71. Palmqvist, R., P. Stattin, et al. (2003). "Plasma insulin, IGF-binding proteins-1 and-2 and risk of colorectal cancer: a prospective study in northern Sweden." Int J Cancer 107(1):89-93.
72. Peyrat, J. P., J. Bonneterre, et al. (1993). "Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer." Eur J Cancer 29A(4): 492-7.
73. Pisani, P. (2008). "Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies." Arch Physiol Biochem 114(1):63-70.
74. Pischon, T., P. H. Lahmann, et al. (2006). "Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC)." J Natl Cancer Inst 98(13):920-31.
75. Platz E. A., M. N. Pollak, et al. (1999). "Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men." Cancer Epidemiol Biomarkers Prev 8(12):1107-10.
76. Platz, E. A., M. N. Pollak, et al. (2005). "Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era." Cancer Causes Control 16(3):255-62.
77. Pollak, M. (2008). "Insulin and insulin-like growth factor signalling in neoplasia." Nat Rev Cancer 8(12):915-28.
78. Pollak, M., W. Beamer, et al. (1998). "Insulin-like growth factors and prostate cancer." Cancer Metastasis Rev 17(4):383-90.
79. Probst-Hensch, N. M., J. M. Yuan, et al. (2001). "IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai." Br J Cancer 85(11):1695-9.
80. Renehan A. G., M. Zwahlen, et al. (2004). "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis." Lancet 363(9418):1346-53.
81. Renehan, A. G., M. Harvie, et al. (2006). "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on." Endocr Relat Cancer 13(2):273-8.
82. Rinaldi, S., R. Cleveland, et al. (2010). "Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies." Int J Cancer 126(7):1702-15.
83. Rinaldi, S., R. Kaaks, et al. (2005). "Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays." Cancer Epidemiol Biomarkers Prev 14(1):48-52.
84. Rinaldi, S., P. H. Peeters, et al. (2006). "IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC)." Endocr Relat Cancer 13(2):593-605.
85. Roddam, A. W., N. E. Allen, et al. (2008). "Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies." Ann Intern Med 149(7):461-71, W83-8.
86. Rollison, D. E., C. J. Newschaffer, et al. (2006). "Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer." Int J Cancer 118(5):1279-84.
87. Ron, E., G. Gridley, et al. (1991). "Acromegaly and gastrointestinal cancer." Cancer 68(8):1673-7.
88. Rowlands, M. A., D. Gunnell, et al. (2009). "Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis." Int J Cancer 124(10):2416-29.
89. Savage, C. J., H. Lilja, et al. (2010) "Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening." Cancer Epidemiol Biomarkers Prev 19(5):1201-7.
90. Schairer, C., McCarty, C.A., Isaacs, C., Sue, L.Y., Pollak, M.N., Berg, C.D., Ziegler, R.G. (2010). "Circulating insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) Cohort." Hormones and Cancer (1): 100-111.
91. Schernhammer, E. S., J. M. Holly, et al. (2006). "Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II." Endocr Relat Cancer 13(2):583-92.
92. Schernhammer, E. S., J. M. Holly, et al. (2005). "Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk." Cancer Epidemiol Biomarkers Prev 14(3):699-704.
93. Schumacher, F. R., I. Cheng, et al. (2010). "A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians." Hum Mol Genet.
94. Severi, G., H. A. Morris, et al. (2006). "Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer." Cancer Epidemiol Biomarkers Prev 15(6):1137-41.
95. Shi R., H. Yu, et al. (2004). "IGF-I and breast cancer: a meta-analysis." Int J Cancer 111(3):418-23.
96. Stattin, P., A. Bylund, et al. (2000). "Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study." J Natl Cancer Inst 92(23):1910-7.
97. Stattin, P., S. Rinaldi, et al. (2004). "High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort." J Clin Oncol 22(15):3104-12.
98. Stocks, T., A. Lukanova, et al. (2007). "Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden." Int J Cancer 120(12):2678-86.
99. Sugumar A., Y. C. Liu, et al. (2004). "Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature." Int J Cancer 111(2):293-7.
100. Toniolo, P., P. F. Bruning, et al. (2000). "Serum insulin-like growth factor-I and breast cancer." Int J Cancer 88(5):828-32.
101. Vatten, L. J., J. M. Holly, et al. (2008). "Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway." Cancer Epidemiol Biomarkers Prev 17(8):2097-100.
102. Verheus, M., P. H. Peeters, et al. (2006). "Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)." Int J Cancer 119(3):659-67.
103. Wei, E. K., E. Giovannucci, et al. (2004). "Comparison of risk factors for colon and rectal cancer." Int J Cancer 108(3):433-42.
104. Wei, E. K., J. Ma, et al. (2005). "A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women." Cancer Epidemiol Biomarkers Prev 14(4):850-5.
105. Weiss, J. M., W. Y. Huang, et al. (2007). "IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial." Int J Cancer 121(10):2267-73.
106. Woodson, K., J. A. Tangrea, et al. (2003). "Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men." Cancer Res 63(14):3991-4.
107. World Cancer Research Fund/American Institute for Cancer, R. (2007). Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective.. Washington DC AICR.
108. Zuccolo, L., R. Harris, et al. (2008). "Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis." Cancer Epidemiol Biomarkers Prev 17(9):2325-36.